Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AstraZeneca PLC (GB:AZN)
LSE:AZN
Holding GB:AZN?
Track your performance easily
AZN Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range9,461.00p - 13,388.00p
Previous Close10,256p
Volume193.43K
Average Volume (3M)2.66M
Market Cap
£159.00B
Enterprise Value176.94B
Total Cash (Recent Filing)$5.84B
Total Debt (Recent Filing)$28.62B
Price to Earnings (P/E)31.0
Beta0.97
Next Earnings
Feb 06, 2025EPS Estimate
£1.69Last Dividend Ex-Date
Aug 08, 2024Dividend Yield2.28%
Share Statistics
EPS (TTM)3.30
Shares Outstanding1,550,317,189
10 Day Avg. Volume2,337,537
30 Day Avg. Volume2,664,282
Standard Deviation0.06
R-Squared0.09
Alpha0.00822
Financial Highlights & Ratios
PEG Ratio4.53
Price to Book (P/B)402.35
Price to Sales (P/S)4.34
Price to Cash Flow (P/CF)19.10
P/FCF Ratio26.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.99
Enterprise Value/Gross Profit4.71
Enterprise Value/Ebitda19.48
Forecast
1Y Price Target
13,765.50pPrice Target Upside33.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
AstraZeneca News
Bulls Say, Bears Say
Bulls Say
Earnings And GuidanceAstraZeneca's guidance has been upgraded to 'high-teens' growth for both revenues and core EPS, reflecting increased confidence in achieving sales-based milestones.
Financial PerformanceSales and revenue grew 21% in the quarter, not showing any slowdown, while operating expenses and more particularly SG&A costs increased at a lower pace.
Growth OutlookAnalysts believe investors are under-appreciating AstraZeneca's long-term prospects, suggesting a potential for growth.
Bears Say
Clinical Trial ConcernsThere are concerns about the toxicity of Volrustomig, with a high percentage of Grade 3/4 treatment-related adverse events and discontinuations.
Market PerformanceThere is a reduction in the Price Target by 10% due to downgrades and peer group multiple contraction.
Regulatory RisksThe China investigation is unhelpful and could result in a fine up to $800m if it expands to AstraZeneca's China organization.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.02% Insiders
14.90% Mutual Funds
0.02% Other Institutional Investors
76.54% Public Companies and
Individual Investors
AZN FAQ
What was AstraZeneca PLC’s price range in the past 12 months?
AstraZeneca PLC lowest share price was 9461.00p and its highest was 13388.00p in the past 12 months.
What is AstraZeneca PLC’s market cap?
Currently, no data Available
When is AstraZeneca PLC’s upcoming earnings report date?
AstraZeneca PLC’s upcoming earnings report date is Feb 06, 2025 which is in 46 days.
How were AstraZeneca PLC’s earnings last quarter?
AstraZeneca PLC released its earnings results on Nov 12, 2024. The company reported 1.655p earnings per share for the quarter, beating the consensus estimate of 1.626p by 0.029p.
Is AstraZeneca PLC overvalued?
According to Wall Street analysts AstraZeneca PLC’s price is currently Undervalued.
Does AstraZeneca PLC pay dividends?
AstraZeneca PLC pays a Annually dividend of 77.6p which represents an annual dividend yield of 2.28%. See more information on AstraZeneca PLC dividends here
What is AstraZeneca PLC’s EPS estimate?
AstraZeneca PLC’s EPS estimate is £1.69.
How many shares outstanding does AstraZeneca PLC have?
AstraZeneca PLC has 1,550,317,100 shares outstanding.
What happened to AstraZeneca PLC’s price movement after its last earnings report?
AstraZeneca PLC reported an EPS of 1.655p in its last earnings report, beating expectations of 1.626p. Following the earnings report the stock price went up 0.05%.
Which hedge fund is a major shareholder of AstraZeneca PLC?
Currently, no hedge funds are holding shares in GB:AZN
---
AstraZeneca Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
13,765.50p (33.98% Upside)
13,765.50p (33.98% Upside)
Insider Transactions
Bought Shares
Worth £2.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.02%
12-Months-Change
Fundamentals
Return on Equity
16.83%
Trailing 12-Months
Asset Growth
-0.64%
Trailing 12-Months
Company Description
AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
---
AZN Stock 12 Month Forecast
Average Price Target
13,765.50p
▲(33.98% Upside)
Technical Analysis
Best Analysts Covering AZN
1 Year
1 Year Success Rate
28/38 ratings generated profit
1 Year Average Return
+10.25%
assigned a buy rating 28 days ago
Copying Emily Field's trades and holding each position for 1 Year would result in 73.68% of your transactions generating a profit, with an average return of +10.25% per trade.
---